Posts

Acalabrutinib FDA approved for treatment of adult patients with pre-treated mantle cell lymphoma

On 31 October 2017, the FDA granted accelerated approval to acalabrutinib (Calquence®, AstraZeneca under license of Acerta Pharma BV) for treatment of adult patients with mantle cell lymphoma (MCL) and pre-treated with one or more prior therapy.